Published in
American Society of Hematology, Blood Advances, 22(3), p. 3590-3601, 2019
DOI: 10.1182/bloodadvances.2019000717
Links
Tools
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
Journal article published in 2019 by
Joshua A. Hill,
Elizabeth M. Krantz,
Kevin A. Hay 
,
Sayan Dasgupta,
Terry Stevens-Ayers,
Rachel A. Bender Ignacio ,
Merav Bar,
Joyce Maalouf,
Sindhu Cherian,
Xueyan Chen,
Greg Pepper,
Stanley R. Riddell,
David G. Maloney,
Michael J. Boeckh,
Cameron J. Turtle
,
Sayan Dasgupta,
Terry Stevens-Ayers,
Rachel A. Bender Ignacio ,
Merav Bar,
Joyce Maalouf,
Sindhu Cherian,
Xueyan Chen,
Greg Pepper,
Stanley R. Riddell,
David G. Maloney,
Michael J. Boeckh,
Cameron J. Turtle
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Virus-specific IgG levels were stable for up to 1 year after CD19-CARTx in adults with durable complete remission. Preexisting humoral immunity may be preserved in adult recipients of CD19-CARTx.